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Background  
For patients with limited life expectancy – typically surviving for less than one year – 
polypharmacy is very common because medication is prescribed to manage acute 
symptoms associated with the life limiting illness (e.g. cancer) and to treat or prevent 
other long-term conditions (e.g. cardiovascular disease).  As a consequence, this 
polypharmacy is linked with an increased risk of developing a drug-related toxicity 
due to the potential of drug-drug or drug-disease interactions.  This risk is further 
heightened in patients with limited life expectancy owing to their unique and dynamic 
pharmacokinetic and pharmacodynamic parameters (e.g. variation in volume of 
distribution or altered drug excretion due to declining renal and/or hepatic function).  
In view of the potential for polypharmacy to cause harm in patients with limited life 
expectancy, it is essential to optimize patients’ medication to align with therapeutic 
goals and life expectancy.  To date, however, there is a growing body of evidence 
that suggests inappropriate medication continues to be prescribed to patients with 
limited life expectancy. 
 
Objectives 
The objectives of this work was to: 
1. Assess the prevalence of inappropriate medication use in patients attending a 
day care centre in a specialist palliative care unit; and, 
2. Identify any potential theoretical drug-drug interactions in this patient group 
using drug interaction recognition software. 
 
Methods 
This was a prospective study that gathered data from December 2012 until February 
2013.  The medication histories for patients attending a day care centre within a 
specialist palliative care unit were accessed along with their medical history.  
Medication was assessed for appropriateness using the conceptual framework 
described by Holmes and colleagues [1] for patients with limited life expectancy.  The 
following factors were considered when deciding on medication appropriateness: 
remaining life expectancy of the patient, time until benefit of the treatment, goals of 
care and treatment targets.  Consensus was reached via Delphi methodology using a 
range of clinical pharmacists and consultants in palliative medicine.  Drug 
interactions were identified and assessed according to significance using the drug 
interaction recognition software, Proscript.  Drug interactions identified as 
significant were then further sub-classified as moderate or severe based upon the 
potential to cause harm or hospitalization, if they were reversible or irreversible and, 
finally, if any treatment would be required to manage the drug interaction.  This work 
was registered as an audit with the Trust and thus ethics approval was not required. 
 
Results  
A total of 66 patients were assessed during the study period, 62 had cancer, 1 
congestive heart failure, 2 severe chronic obstructive pulmonary disease and 1 
Parkinson’s disease.  In total, the number of medications taken was 715 (mean per 
patient, 11; range 1 to 21).  Using the conceptual framework as a guide, from the 715 
medicines assessed, 101 (15 per cent) were considered to be inappropriate given 
the patients’ limited life expectancy.  Out of the 66 patients assessed, 44 (67 per 
cent) were taking at least one inappropriate medication.  The most common 
medication considered inappropriate were the statins that were prescribed in 16 
patients (24 per cent).  Other common inappropriate medications were aspirin in 11 
patients (17 per cent), calcium supplements in 10 patients (15 per cent) and ACE 
inhibitors in 10 patients (15 per cent). 
 
The drug interaction recognition software identified a total of 104 potential drug 
interactions occurring in 39 patients (59 per cent): 54 were considered non-significant, 
while 50 were classified as significant.  Among those identified as significant, 43 
were considered moderate while 7 were considered severe.  In our study, 
discontinuing inappropriate medicine would prevent 22 non-significant, 12 moderate 
and 4 severe potential drug interactions. Among patients identified as having a 
potential drug interaction, discontinuing inappropriate medication would prevent at 
least one potential drug interaction in 18 patients (46 per cent).  The most frequent 
major potential drug interaction that could be prevented by discontinuing 
inappropriate medication was between simvastatin (> 40 mg OD) and amlodipine, a 
well-defined drug interaction, which increases the risk of myopathy; this was 
identified in three patients.  Another major potential drug interaction that could be 
prevented was identified between haloperidol and quinine sulphate, an interaction 
that increases the risk of developing torsade de pointes – a serious ventricular 
tachycardia. 
 
Discussion 
Our results show that the majority of people accessing the day care centre in a 
specialist palliative care unit are using many inappropriate medications in view of 
their life limiting illness.  These inappropriate medications contribute to potential drug 
interactions and thereby increase the risk of a patient developing a drug-related 
toxicty.  Our findings are in agreement with the literature and build upon our previous 
work that showed patients with advanced lung cancer take many inappropriate 
medications – some of which can potentially interact with chemotherapy potentially 
causing negative outcomes for patients.[2]  
 
 
In view of these findings, there is potential for pharmacists to become involved in the 
review of patients with limited life expectancy to faciliate discontinuing inappropriate 
medication.  However, unlike discontinuing medicines in elderly patients – where the 
STOPP-START [3] and Beers criteria [4] can be used – there is a lack of appropriate 
guidance for discontinuing inappropriate medication in patients with limited life 
expectancy. The framework used in this study is highly conceptual and does not 
neccesarily lend its application to a busy clinical environment.  Further guidence is 
thus required to assist clinicans in decision-making around discontinuing 
inappropriate medication in patients with limited life expectancy. 
 
Conclusions 
Patients who accessed the day care center in the specialist palliative care unit take 
many inappropriate medications in view of their limited life expectancy.  These 
medications not only increase the pill burden for the patient but also increase the 
possibility of developing a drug related toxicity. These patients should have their 
medications reviewed in the context of their original therapeutic goals taking into 
account their life-limiting diagnosis.   
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